Login
Super Investors Versant Venture Management, LLC
VV

Versant Venture Management, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$109M
Positions
8
Quarter ended
September 30, 2026
Filed
November 13, 2026

Reported portfolio value by quarter (48 quarters reported)

$963M $48M
Q4 14 Q2 17 Q4 19 Q2 22 Q4 24 Q3 26

$105M in Q4 2014 → $109M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Monte Rosa Therapeutics, Inc. 34.8% Unchanged 3,180,780 $37.9M
Century Therapeutics, Inc. 19.1% Unchanged 12,166,109 $20.8M
Contineum Therapeutics, Inc. 15.9% Added 138% 1,292,628 $17.3M
Jade Biosciences, Inc. 12.8% Unchanged 991,783 $13.9M
Lenz Therapeutics, Inc. 9.4% Unchanged 2,656,888 $10.2M
Crispr Therapeutics Ag 7.5% Unchanged 148,831 $8.23M
Skye Bioscience, Inc. 0.4% New 250,962 $404K
Tempest Therapeutics, Inc. 0.2% Unchanged 269,772 $225K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 13, 2026

Company Action Shares changed Value of change % of portfolio
Contineum Therapeutics, Inc. Added +750,000 +$10.1M 15.9%
Skye Bioscience, Inc. Exited −2,007,704 −$1.39M —
Skye Bioscience, Inc. New +250,962 +$404K 0.4%

Q2 2026

quarter ended June 30, 2026 · filed August 12, 2026

Company Action Shares changed Value of change % of portfolio
Jade Biosciences, Inc. Trimmed −534,037 −$11.9M 13.6%

Q1 2026

quarter ended March 31, 2026 · filed May 05, 2026

Company Action Shares changed Value of change % of portfolio
Century Therapeutics, Inc. New +12,166,109 +$27.5M 19.4%
Monte Rosa Therapeutics, Inc. Trimmed −1,201,907 −$19.8M 37.0%

Q4 2025

quarter ended December 31, 2025 · filed February 12, 2026

Company Action Shares changed Value of change % of portfolio
Monte Rosa Therapeutics, Inc. Trimmed −1,270,235 −$19.9M 45.5%
Repare Therapeutics, Inc. Exited −2,646,657 −$4.66M —
Adverum Biotechnologies, Inc. Exited −506,821 −$2.3M —

Q3 2025

quarter ended September 30, 2025 · filed November 10, 2025

Company Action Shares changed Value of change % of portfolio
Lenz Therapeutics, Inc. New +2,656,888 +$124M 58.3%
Crispr Therapeutics Ag Trimmed −349,727 −$22.7M 4.5%

Q2 2025

quarter ended June 30, 2025 · filed August 11, 2025

Company Action Shares changed Value of change % of portfolio
Jade Biosciences, Inc. New +1,525,820 +$15.2M 18.6%
Tempest Therapeutics, Inc. Exited −3,507,055 −$2.59M —
Tempest Therapeutics, Inc. New +269,772 +$1.83M 2.2%
Contineum Therapeutics, Inc. Trimmed −375,535 −$1.49M 2.6%

Q1 2025

quarter ended March 31, 2025 · filed May 07, 2025

Company Action Shares changed Value of change % of portfolio
Tempest Therapeutics, Inc. Exited −3,507,055 −$2.93M —
Tempest Therapeutics, Inc. New +3,507,055 +$2.59M 4.3%

Q4 2024

quarter ended December 31, 2024 · filed February 12, 2025

Company Action Shares changed Value of change % of portfolio
Monte Rosa Therapeutics, Inc. New +5,652,922 +$39.2M 45.2%
Tempest Therapeutics, Inc. New +3,507,055 +$2.93M 3.4%
Gritstone Oncology, Inc. Exited −3,561,150 −$2.07M —

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support